Marvel Biosciences Corp.MRVL.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada

Marvel Biosciences Corp. is a pre-clinical stage pharmaceutical development company based in Calgary, Canada, that employs a drug redevelopment approach to identify and evaluate therapeutic compounds for new disease indications. The company's lead compound, MB-204, is a novel fluorinated derivative of istradefylline — an adenosine A2a receptor antagonist — being investigated for the treatment of Alzheimer's disease, autism spectrum disorder, depression, and anxiety.

Key ratios

ROA

-172.1%TTM

2025 -227.7%2024 -131.6%2023 -172.8%

Recent news

Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million 2026-09-17 · Newsfile Marvel Biosciences Announces Extension to Closing Date of Private Placement 2026-09-09 · Newsfile Marvel Biosciences Announces Grant of Deferred Share Units 2026-09-01 · Newsfile Marvel Biosciences Expands Private Placement to Quebec 2026-08-19 · Newsfile Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X 2026-08-05 · GlobeNewswire Marvel Biosciences Announces Private Placement for up to $3.0 Million 2026-07-16 · Newsfile Marvel Biosciences Announces Grant of Deferred Share Units 2026-05-20 · Newsfile Corp.Marvel Biosciences Announces Closing of Convertible Debenture Offering 2026-04-17 · Newsfile Corp.Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204 2026-03-18 · Newsfile Corp.

Track MRVL.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer